ficlatuzumab
mAbexperimental
Ficlatuzumab is a humanized monoclonal antibody designed for the treatment of cancers. — Wikipedia
Clinical trial activity
13 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00725634)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Glioblastoma · Phase 1
- Head and Neck Neoplasms · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1
- Multiple Myeloma · Phase 1
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Oropharyngeal Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Respiratory Tract Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 3
Mechanism of action
- Hepatocyte growth factorINHIBITOR
HGF inhibitor
Humanized IgG1 antibody that binds the HGF ligand with high affinity and specificity, thus inhibiting c-MET/HGF biological activities.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFiclatuzumab ↗
- ChEMBLCHEMBL1743018 ↗
Also known as
- av-299
- av-299
- av-299
- ficlatuzumab
- ficlatuzumab
- ficlatuzumab
- ficlatuzumab
- sch 900105
- sch-900105
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06064877 | Phase 3 | Nov 30, 2023 | AVEO Pharmaceuticals |
| NCT04100330 | Phase 2 | Dec 16, 2019 | AVEO Pharmaceuticals, Biodesix Inc. |
| NCT03316599 | Phase 1 | Jan 17, 2018 | AVEO Pharmaceuticals, Harvard University |
| NCT03422536 | Phase 2 | Dec 5, 2017 | National Cancer Institute (NCI), University of Arizona |
| NCT02277184 | Phase 1 | Sep 1, 2015 | AVEO Pharmaceuticals, University of Pittsburgh |
| NCT02277197 | Phase 1 | Aug 1, 2015 | AVEO Pharmaceuticals, University of Pittsburgh |
| NCT02109627 | Phase 1 | Jan 1, 2015 | AVEO Pharmaceuticals, University of California, San Francisco |
| NCT02318368 | Phase 2 | Nov 1, 2014 | AVEO Pharmaceuticals, Biodesix Inc. |
| NCT02090127 | N/A | Mar 14, 2014 | AVEO Pharmaceuticals |
| NCT01189513 | Phase 1 | Aug 1, 2010 | Schering-Plough, University of Texas at Houston |
| NCT01039948 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2009 | AVEO Pharmaceuticals |
| NCT00969410 | Phase 1 | Aug 1, 2009 | AVEO Pharmaceuticals |
| NCT00725634 | Phase 1 | Sep 1, 2008 | AVEO Pharmaceuticals |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AVEO Pharmaceuticals | For profit | 11 | 7 | 4 | 2008 |
| Biodesix Inc. | For profit | 2 | 0 | 1 | 2014 |
| University of Pittsburgh | Academic/Hospital | 2 | 2 | 1 | 2015 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| Schering-Plough | For profit | 1 | 0 | 1 | 2010 |
| University of Arizona | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2015 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2010 |
9 organizations
Page 1 / 1